Genmab Outlicenses Zanolimumab to TenX Biopharma(08 Feb 2010) Genmab A/S announced that it has closed a license agreement under which Genmab has granted exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4®) to TenX Biopharma, Inc.Under the terms of the agreement, Genmab receives a ...
Genmab announces start of ofatumumab Phase III head to head study(12 Nov 2009) Genmab A/S announced the initiation of a Phase III study of Arzerra™ ofatumumab plus chemotherapy versus rituximab plus chemotherapy to treat patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). "The start of this study marks ...
GSK and Gemab receive accelerated approval for Arzerra(27 Oct 2009) GlaxoSmithKline (GSK) and Genmab A/S announced the accelerated approval of ArzerraTM (ofatumumab) from the US Food and Drug Administration for use in patients with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and ...
Genmab annouces positive top-line results for Arzerra(27 Aug 2009) Genmab A/S announced positive top-line results from the Phase II study of Arzerra™ (ofatumumab) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with previously untreated follicular non-Hodgkin’s ...
Genmab announces preliminary top-line results for Arzerra in front line CLL(12 Aug 2009) Genmab A/S announced top-line results from the Phase II study of Arzerra™ (ofatumumab) in combination with fludarabine and cyclophosphamide (FC) to treat chronic lymphocytic leukemia (CLL) in previously untreated patients.A total of 61 patients were ...
Genmab: Recruitment Completed in Arzerra (Ofatumumab) Phase II Study in Relapsed DLBCL(27 Jul 2009) Genmab A/S announced it has completed recruitment of 75 patients in the Phase II study of Arzerra(TM) (ofatumumab) to evaluate treatment of relapsed Diffuse Large B-Cell Lymphoma (DLBCL) in patients ineligible for or relapsed following a stem cell ...
Top
